Ciprocopan Receives Marketing Approval in China for Untreated PNH Patients
Nuvectis Pharma announced that ciprocopan (NXP100), a once-daily oral complement Factor B inhibitor, received marketing approval from the National Medicinal Products Administration of China for treating patients with Paroxysmal Nocturnal Hemoglobinuria who have not previously used Complement inhibitors. This marks its first global approval and highlights potential in multiple complement-mediated diseases.
Topics: biotech complement inhibitors pharmaceuticals PNH treatment